1. UTime Limited signed a $10M smart health device procurement agreement. 2. The deal involves 50,000 premium health devices for North America. 3. CEO highlights significant breakthrough in the North American wearable market. 4. UTime targets explosive growth in the smart health device market. 5. Initial deliveries start in Q1 2026, with quality control measures.
FAQ
Why Bullish?
The substantial order reflects growing market demand and UTime's strategic position. Historical precedents show that similar collaborations often lead to share price increases.
How important is it?
A $10M contract significantly raises UTime's profile in the competitive smart health sector.
Why Short Term?
Immediate delivery timeline suggests prompt market integration of their products, impacting short-term stock performance.
UTime Limited Secures $10 Million Mega Order to Expand in North America
SHENZHEN, China, Dec. 31, 2025 (GLOBE NEWSWIRE) -- UTime Limited (Nasdaq: WTO), a leading technology company specializing in mobile device design and development, has achieved a significant milestone in its expansion efforts. UTime's Hong Kong subsidiary, UTime Technology (HK) Company Limited, has formalized a smart health device procurement agreement valued at nearly $10 million USD with Tumu Vertex LLC, located in Denver. This agreement marks a critical advancement for UTime in the burgeoning North American medical-grade smart wearable market.
Details of the Major Purchase Agreement
Under the signed Sales Agreement, Tumu Vertex LLC has requested an impressive initial order of 50,000 high-quality smart health devices from UTime, including:
- 25,000 units of the UT-168 BT Blood Pressure Watch
- 25,000 units of the UR08 ECG Smart Ring
- 25,000 units of the UT-368 4G Blood Pressure Watch
- 25,000 units of the UR01 Smart Ring
This collaboration is not just a leap in volume; it signals a new level of technological integration in UTime's offerings. The devices marry FDA-certified medical-grade monitoring technology with practical, everyday use, reflecting the latest trends in the smart health sector.
Strategic Significance of the Agreement
"This cooperation represents a significant strategic breakthrough for us in the North American market," stated UTime's CEO during the signing event. "Tumu Vertex's order for 50,000 units is a testament to the market's recognition of our technological capabilities and paves the way for our entry into the medical-grade wearable market in North America. We intend to harness this opportunity to fast-track the development of next-generation health monitoring technologies as part of our expanding product portfolio."
Monil Hossain, the founder and CEO of Tumu Vertex LLC, remarked, "UTime's technological innovation and product quality have deeply impressed us. These devices are set to enhance our smart health service platform in the United States, providing users with continuous health monitoring solutions. We look forward to building a long-term strategic partnership with UTime."
Future Outlook and Market Growth Potential
The initial delivery of products is scheduled for the first quarter of 2026 and will undergo comprehensive quality control processes as established by both companies. With global populations experiencing increased longevity and health awareness, UTime anticipates substantial growth in the smart health device sector. This pivotal order is expected to solidify UTime's position within the consumer electronics industry while establishing a foundational strategy for growth in the medical technology arena.
About UTime Limited
UTime Limited, trading under the NASDAQ ticker symbol WTO, focuses on the design, development, production, and marketing of mobile devices and smart wearables, both in China and globally. The company seeks to deliver cost-effective products to a wide-ranging customer base, enhancing its competitive edge in the tech industry.
Safe Harbor Statement
This announcement contains forward-looking statements as defined in Section 21E of the Securities Exchange Act of 1934. While these statements address anticipated future performance, they involve known and unknown risks and uncertainties that could cause actual results to differ significantly. For risks, please refer to UTime Limited's Annual Report on Form 20-F and other SEC filings. Forward-looking statements are made as of the date of this release, with no obligation for the company to update them as future events unfold.
Contact Information
UTime Limited
7th Floor, Building 5A
Shenzhen Software Industry Base
Nanshan District, Shenzhen, People’s Republic of China 518061
Tel: (86) 755 865122
Email: qhengcong@utimemobile.com